Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 129, Issue 12, Pages 5163-5168Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI129057
Keywords
-
Categories
Funding
- Morris Kahn Foundation
- National Knowledge Center for Rare/Orphan Diseases - Israeli Ministry of Science, Technology and Space
Ask authors/readers for more resources
Gout is caused by deposition of monosodium urate crystals in joints when plasma uric acid levels are chronically elevated beyond the saturation threshold, mostly due to renal underexcretion of uric acid. Although molecular pathways of this underexcretion have been elucidated, its etiology remains mostly unknown. We demonstrate that gout can be caused by a mutation in LDHD within the putative catalytic site of the encoded D-lactate dehydrogenase, resulting in augmented blood levels of D-lactate, a stereoisomer of L-lactate, which is normally present in human blood in miniscule amounts. Consequent excessive renal secretion of D-lactate in exchange for uric acid reabsorption culminated in hyperuricemia and gout. We showed that LDHD expression is enriched in tissues with a high metabolic rate and abundant mitochondria and that D-lactate dehydrogenase resides in the mitochondria of cells overexpressing the human LDHD gene. Notably, the p.R370W mutation had no effect on protein localization. In line with the human phenotype, injection of D-lactate into naive mice resulted in hyperuricemia. Thus, hyperuricemia and gout can result from the accumulation of metabolites whose renal excretion is coupled to uric acid reabsorption.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available